Skip to main content
Premium Trial:

Request an Annual Quote

NCI, BioFortis, GeneGo, NIGMS, NIH, NCBC



NCI to Use BioFortis' Labmatrix Software

BioFortis said this week that the National Cancer Institute will use its Labmatrix software in the Center for Cancer Research.

Labmatrix is a web-based, enterprise translational research information-management software platform. It integrates clinical data with genomic, proteomic, and laboratory experimental data, and maintains annotated tissue banks.

The National Institutes of Health collaborated with BioFortis in developing Labmatrix.

CCR is composed of multiple labs, branches, and core facilities supporting both clinical and basic sciences, with a focus on translational cancer research.

NJ's Reproductive Medicine Associates Licenses GeneGo's MetaCore

GeneGo said this week that it has licensed its MetaCore technology to the Reproductive Medicine Associates of New Jersey.

The facility will use the tool to analyze gene-expression data in research and in its clinic. Julie Bryant, vice president of business development at GeneGo, said in a statement that this is the first time MetaCore will be used by healthcare practitioners instead of pharmaceutical companies or academic groups.

Financial details for the multi-year agreement were not disclosed.

NIGMS Sets Aside $10M for Systems Bio Research; RFA Applications Due Nov. 1

The National Institute of General Medical Sciences has set aside approximately $10 million in fiscal year 2007 under a request for applications to fund three new and/or competing continuation grants in the field of systems biology.

NIGMS said it will fund studies that "promote institutional development of pioneering research, training, and outreach programs focused on systems level analysis of biological phenomena of biomedical importance within the NIGMS mission."

The NIH agency will support "fundamental inquiries focused on molecular and cell biology, biophysics, genetics and developmental biology, pharmacology, anesthesiology, and human physiology in the areas of trauma, burn, inflammation, and multi-organ failure," the RFA said.

The RFA, which is a reissue of a 2004 program, covers:

  • Signaling networks and the regulatory dynamics of cellular processes such as cell cycle control, transient complex formation, organelle biogenesis, and intercellular communications;
  • Supramolecular machines, such as the replisome, spliceosome, and molecular motor assemblies in cell division and motility;
  • Pattern formation and developmental processes in model systems (e.g., Drosophila, C. elegans, etc.);
  • Metabolic networks and the control of the flux of substrates, intermediates, and products in cell physiology;
  • Organ system networks involved in multi-organ failure in shock, trauma, and burn injury; and
  • Architecture of biological complexity related to inherited variation and its environmental context.

Applicants may request a project period of up to five years and a budget for direct costs up to $2 million per year, NIGMS said. They may ask for more than this amount to pay for "initial large equipment" purchases, with certain restrictions.

Letters of intent should be received by Oct. 23 and applications should be received by Nov. 1, according to the NIGMS. Earliest anticipated start date is July 1, 2007.

Additional information can be found at

NIH to Hold NCBC All Hands Meeting Next Week

The National Institutes of Health will host an "all hands" meeting for NIH Roadmap National Centers for Biomedical Computing centers July 17-19 at the NIH campus in Bethesda, Md.

The meeting will enable the Centers to learn more about each other's scientific and technical programs and to discuss areas of mutual interest, NIH said.

Additional information and the meeting agenda are available at

Filed under

The Scan

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.

Study Points to Benefits of Local Consolidative Therapy, Targeted Treatments in Cancer Care

In JCO Precision Oncology, researchers report that local consolidative therapy combined with molecularly targeted treatments could improve survival for some lung cancer patients.

Genetic Variants That Lower LDL Cholesterol Linked to Reduced Heart Disease Risk

Rare variants in two genes that lower LDL cholesterol are also associated with a decreased risk of coronary heart disease, according to a new JAMA Cardiology study.

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.